Second tumors in children with hematological malignancies

Background. Hemoblastoses treatment success in children made it possible to cure the vast majority of patients. The follow-up period exceeds tens of years, during which the problem of second tumors (ST) becomes urgent.  The objective of the study was to characterize ST in patients who underwent a ma...

Full description

Bibliographic Details
Main Authors: N. A. Susuleva, T. T. Valiev, N. S. Martynova, S. N. Mikhaylova
Format: Article
Language:Russian
Published: ABV-press 2021-04-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/462
_version_ 1797855521173143552
author N. A. Susuleva
T. T. Valiev
N. S. Martynova
S. N. Mikhaylova
author_facet N. A. Susuleva
T. T. Valiev
N. S. Martynova
S. N. Mikhaylova
author_sort N. A. Susuleva
collection DOAJ
description Background. Hemoblastoses treatment success in children made it possible to cure the vast majority of patients. The follow-up period exceeds tens of years, during which the problem of second tumors (ST) becomes urgent.  The objective of the study was to characterize ST in patients who underwent a malignant tumor of hematopoietic and lymphoid tissues at the age of 0 to 18 years.Materials and methods. The study included 64 patients with ST development in the period from 1 to 38 years.Results. Most frequently ST developed after treatment of Hodgkin's lymphoma (45.3 %) and acute lymphoblastic leukemia (35.9 %), supported by high cumulative doses of alkylating agents and radiation therapy. Among STs, in 35.9 % of cases, thyroid cancer was diagnosed, in 10.9 % - acute leukemia, in 9.4 % - tumors of the central nervous system.  The results of ST treatment are significantly worse than those of primary tumors. Thus, of 64 patients with ST, 46 (71.9 %) are alive, death from ST progression was noted in 18 (28.1 %) cases.Conclusion. Improvement of modern treatment protocols aimed at reducing the indications for radiation therapy and cumulative doses of alkylating agents, along with the development of effective follow-up programs for children cured of hematological malignancies, will probably help reduce the ST incidence.
first_indexed 2024-04-09T20:23:58Z
format Article
id doaj.art-1e7cdaf415d74d2ca9a084c855630e0c
institution Directory Open Access Journal
issn 1818-8346
2413-4023
language Russian
last_indexed 2024-04-09T20:23:58Z
publishDate 2021-04-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj.art-1e7cdaf415d74d2ca9a084c855630e0c2023-03-30T20:15:13ZrusABV-pressОнкогематология1818-83462413-40232021-04-01161364610.17650/1818-8346-2021-16-1-36-46380Second tumors in children with hematological malignanciesN. A. Susuleva0T. T. Valiev1N. S. Martynova2S. N. Mikhaylova3Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaBackground. Hemoblastoses treatment success in children made it possible to cure the vast majority of patients. The follow-up period exceeds tens of years, during which the problem of second tumors (ST) becomes urgent.  The objective of the study was to characterize ST in patients who underwent a malignant tumor of hematopoietic and lymphoid tissues at the age of 0 to 18 years.Materials and methods. The study included 64 patients with ST development in the period from 1 to 38 years.Results. Most frequently ST developed after treatment of Hodgkin's lymphoma (45.3 %) and acute lymphoblastic leukemia (35.9 %), supported by high cumulative doses of alkylating agents and radiation therapy. Among STs, in 35.9 % of cases, thyroid cancer was diagnosed, in 10.9 % - acute leukemia, in 9.4 % - tumors of the central nervous system.  The results of ST treatment are significantly worse than those of primary tumors. Thus, of 64 patients with ST, 46 (71.9 %) are alive, death from ST progression was noted in 18 (28.1 %) cases.Conclusion. Improvement of modern treatment protocols aimed at reducing the indications for radiation therapy and cumulative doses of alkylating agents, along with the development of effective follow-up programs for children cured of hematological malignancies, will probably help reduce the ST incidence.https://oncohematology.abvpress.ru/ongm/article/view/462hematological malignanciessecond tumorchemotherapyradiation therapychildren
spellingShingle N. A. Susuleva
T. T. Valiev
N. S. Martynova
S. N. Mikhaylova
Second tumors in children with hematological malignancies
Онкогематология
hematological malignancies
second tumor
chemotherapy
radiation therapy
children
title Second tumors in children with hematological malignancies
title_full Second tumors in children with hematological malignancies
title_fullStr Second tumors in children with hematological malignancies
title_full_unstemmed Second tumors in children with hematological malignancies
title_short Second tumors in children with hematological malignancies
title_sort second tumors in children with hematological malignancies
topic hematological malignancies
second tumor
chemotherapy
radiation therapy
children
url https://oncohematology.abvpress.ru/ongm/article/view/462
work_keys_str_mv AT nasusuleva secondtumorsinchildrenwithhematologicalmalignancies
AT ttvaliev secondtumorsinchildrenwithhematologicalmalignancies
AT nsmartynova secondtumorsinchildrenwithhematologicalmalignancies
AT snmikhaylova secondtumorsinchildrenwithhematologicalmalignancies